Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Neuro-Oncology Advances|May 25, 2022
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastomaJohn F de Groot, Albert H Kim, Sujit Prabhu, et al.
Neurosurgery|June 20, 2019
Letter: When Less is More: Dexamethasone Dosing for Brain TumorsMary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, et al.
Neuro-Oncology Advances|April 28, 2023
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experienceTimothy A Gregory, Maximilian Mastall, Heather Lin, et al.
Nature Communications|April 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trialShiao-Pei Weathers, Xiqi Li, Haifeng Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Neuro-Oncology|June 9, 2019
Barriers to accrual and enrollment in brain tumor trialsEudocia Q Lee, Ugonma N Chukwueke, Shawn L Hervey-Jumper, et al.
Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
JAMA Oncology|June 18, 2025
Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical TrialDebra Nana Yeboa, Jing Li, Ruitao Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialPatrick Y Wen, Mehdi Touat, Brian M Alexander, et al.
Nature|November 22, 2019
Longitudinal molecular trajectories of diffuse glioma in adultsFloris P Barthel, Kevin C Johnson, Frederick S Varn, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Neuro-Oncology Advances|May 25, 2022
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastomaJohn F de Groot, Albert H Kim, Sujit Prabhu, et al.
Neurosurgery|June 20, 2019
Letter: When Less is More: Dexamethasone Dosing for Brain TumorsMary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, et al.
Neuro-Oncology Advances|April 28, 2023
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experienceTimothy A Gregory, Maximilian Mastall, Heather Lin, et al.
Nature Communications|April 27, 2025
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trialShiao-Pei Weathers, Xiqi Li, Haifeng Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Neuro-Oncology|June 9, 2019
Barriers to accrual and enrollment in brain tumor trialsEudocia Q Lee, Ugonma N Chukwueke, Shawn L Hervey-Jumper, et al.
Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
JAMA Oncology|June 18, 2025
Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical TrialDebra Nana Yeboa, Jing Li, Ruitao Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2019
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialPatrick Y Wen, Mehdi Touat, Brian M Alexander, et al.
Nature|November 22, 2019
Longitudinal molecular trajectories of diffuse glioma in adultsFloris P Barthel, Kevin C Johnson, Frederick S Varn, et al.
Pageof 13